AI-Powered Pathology with HALO®, HALO AI, and HALO Link 4.0 | June 6

Supercharge your Image analysis with AI-powered HALO 4.0

AI-Powered Pathology with HALO®, HALO AI, and HALO Link 4.0

Date: 6 June 2024
Time: 7:00 – 8:00 PDT | 10:00 – 11:00 EDT | 15:00 – 16:00 BST
Location: Webinar

Summary

Join Indica Labs for this 1-hour webinar to see a live demonstration of the new versions of the industry leading AI-powered HALO® and HALO AI digital pathology image analysis platform and the HALO Link collaborative image management platform. Mark Bates, Field Applications Scientist at Indica Labs, will demonstrate the ease of use, scalability, and AI-empowered analytic capabilities of HALO and HALO AI 4.0 in workflows leveraging many of the new features from the latest release. Mark will also demonstrate how HALO Link 4.0 empowers users to safely and securely manage, share, and analyze digital slides and data, with new features to further optimize and streamline pathology workflows.

Learning Objectives

  • Learn about HALO’s image analysis modules and workflows for brightfield and fluorescence imaging 
  • Learn how HALO AI can be incorporated into common image analysis workflows for advanced tissue classification, cell segmentation, and cell phenotyping 
  • Learn how HALO Link allows users to manage studies, incorporate images and metadata, and visualize data 

Presenter

Dr. Mark Bates
Field Applications Scientist
Indica Labs

Mark Bates is a Field Applications Scientist at Indica Labs and has a strong background in cancer biology with a particular interest in molecular pathology, the tumor microenvironment, diagnostic, prognostic and predictive biomarkers, and digital pathology. Mark received his PhD from Trinity College Dublin in Ireland and worked as a postdoctoral fellow at the Trinity Translational Medical Institute and the University of St. Andrews in Scotland. During his research career Mark was involved in a number of biomarker projects spanning across the cancer space including projects in cervical, ovarian, prostate, and esophageal cancers as well as liquid biopsies. 

Share This Post